Marketer of the Year will celebrate its 25th anniversary at The Tower Hotel, London on Thursday 15 November, alongside Communications Team of the Year and the all-new Sales Awards.
News
Have you entered yet?
International Clinical Researcher of the Year is celebrating its 20th anniversary in 2019. If ever there was a time to stand out against the competition and be remembered, it’s now!
Individuals from a wide array of companies flock to enter new awards scheme for medical and scientific professionals
There are only two weeks to go until the 31 October deadline, don’t miss it – get your entry in now!
Highlighting this important area of work within the pharmaceutical industry, the new Medical & Scientific Excellence Awards are designed to recognise the outstanding achievements of medical and scientific professionals.
Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
FDA advisory committee backs Shire’s prucalopride
Shire’s prucalopride has taken a giant leap towards approval after winning the support of an FDA advisory committee for chronic idiopathic constipation.
US filing for ViiV’s two-drug, single pill HIV treatment
ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV.
NICE rejects Lilly’s breast cancer drug Verzenios
As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
Gov’t to introduce tech standards for the NHS
Health secretary Matt Hancock has unveiled his vision for technology in healthcare, which, he claims, will lay the foundation for a new generation of digital services able to meet the needs of clinicians, patients and managers.
NHS green light for Novartis skin cancer combo
The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.
Allergan to file ubrogepant for migraine early next year
Allergan is gearing up to file its oral CGRP receptor ubrogepant in the US for the treatment of migraine, following the success and completion of two safety studies.
Novartis buys Endocyte for $2.1 billion
Novartis has signed a deal to acquire US biopharma Endocyte, securing itself access to novel radiopharmaceutical programmes “with significant sales potential”.
London’s health and care system hampering STP progress, finds report
London’s “complex and cluttered” health and care system is holding back plans to improve the health of its population, finds a new independent report from The King’s Fund.
AZ/MSD’s Lynparza assigned Orphan status in US
AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.
Another Humira biosimilar hits EU shores
Samsung Bioepis has announced the European launch of Humira biosimilar Imraldi, as NHS chiefs tell Trusts to ensure they are ready to realise the potential savings from using cheaper versions of the world’s biggest selling drug.
UK launch for first eosinophilic oesophagitis drug
Dr Falk Pharma has launched Jorveza – the first globally licensed drug approved for eosinophilic oesophagitis – across the UK.
